Prevention of Endoleaks Using Autologous Platelet Gel on Unruptured

Status Terminated

Clinical Trial Summary

The main risk of aortic aneurysms is rupture that leads to a high risk of death. A preventive surgical treatment is thus needed. In order to reduce the morbidity and mortality associated with conventional surgery, an endovascular approach (insertion of an endovascular stent graft)is now widely favored. The main problem of this procedure is the occurrence of endoleaks (persistence of a communication between the aneurysm and the aorta). A new approach is proposed to prevent these endoleaks. The principle is to draw blood from the patient, separate the blood from the platelets, and reinject both platelet rich plasma (PRP) and autologous thrombin, in order to form a platelet gel (PRP + autologous thrombin). Before studying the efficacy of this technique, its safety of use and feasibility must be evaluated.

Clinical Trial Description

The main risk of aortic aneurysms is rupture. Onset is usually sudden, leading to the death of the patient in 80% to 90% of cases. The elective treatment of abdominal aortic aneurysms, therefore, seems to be a priority. In order to reduce the morbidity and mortality associated with conventional surgery, an endovascular approach (insertion of an endovascular stent graft using the endovascular aneurysm repair procedure) is now widely favored. The main problem, during follow-up of patients wearing an endovascular stent graft, is the occurrence of endoleaks resulting in retrograde filling of the aneurysm sac. The ideal is to prevent these endoleaks either by new developments in endovascular stent grafts or by using adjuvant therapy during the procedure. The principle is to draw blood from the patient, separate the blood from the platelets, and reinject it into two separate catheters, one with platelet rich plasma (PRP) and the other with autologous thrombin, in order to form a platelet gel (PRP + autologous thrombin). Before studying the efficacy of this technique, its safety of use and feasibility must be evaluated. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00372138
Study type	Interventional
Source	Rennes University Hospital
Contact
Status	Terminated
Phase	N/A
Start date	September 2006
Completion date	July 2008

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT02888613` - Mini-laparotomy Versus Mini Lumbotomy	N/A
Recruiting	`NCT00662480` - Randomized Preventive Vascular Screening Trial of 65-74 Year Old Men in the Central Region of Denmark	Phase 4
Completed	`NCT00989729` - Preoperative Methylprednisolone in Endovascular Aortic Repair	N/A
Active, not recruiting	`NCT02345005` - Iliac Branch Excluder ReGistry (IceBERG)
Completed	`NCT01390740` - Observatory of Screening Aneurysms of the Abdominal Aorta During Echocardiography. National Epidemiological Survey
Completed	`NCT00833924` - Zenith(R) Low Profile AAA Endovascular Graft Clinical Study	N/A
Terminated	`NCT00610090` - Safety Study for the Treatment of Abdominal Aortic Aneurysms	Phase 2
Completed	`NCT02477111` - European (EU) Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms
Recruiting	`NCT01538056` - Physician Modified Endovascular Grafts	N/A
Completed	`NCT01106391` - A Multicenter, Open Label, Prospective, Non-Randomized Study Of INCRAFT™ In Subjects With AAA (INNOVATION)	N/A
Terminated	`NCT00444821` - The (PIVOTAL) Study	N/A
Completed	`NCT01599533` - Screening for Thoracic Aortic Aneurysm Among a Cohort of Patients With a Degenerative Abdominal Aortic Aneurysm	N/A
Completed	`NCT01328197` - Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms	Phase 1
Completed	`NCT00705718` - Endurant Bifurcated and Aorto-Uni-Iliac (AUI) Stent Graft System	N/A
Completed	`NCT02125890` - Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms	Phase 3
Completed	`NCT00875563` - Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study	N/A
Completed	`NCT02048514` - The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms	N/A
Terminated	`NCT00546013` - Abdominal Aortic Aneurysms and Pseudoexfoliation Syndrome	N/A
Recruiting	`NCT05004051` - ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA
Withdrawn	`NCT03965364` - China Post-market Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INITIATION)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prevention of Endoleaks Using Autologous Platelet Gel on Unruptured Abdominal Aortic Aneurysms

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms